In a study of 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years. Although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of iJAMA/i. Tumor necrosis factor I (TNF-I) antagonists ...
Read More
No comments:
Post a Comment